コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 erminal pro-B-type natriuretic peptide], and galectin-3).
2 functional beta-galactoside-binding protein, galectin-3.
3 homonas depleted the extracellular levels of galectin-3.
4 s against FcepsilonRI, FcepsilonRII/CD23 and galectin-3.
5 liver production of the profibrotic lectin, galectin-3.
6 factor, transforming growth factor beta, and galectin-3.
7 ntly after preloading with exogenously added galectin-3.
8 phosphorylation beyond the known example of galectin-3.
9 iguration for discovery of new inhibitors of galectin-3.
10 ed higher levels of extracellular release of galectin-3.
11 s type 1 (HSV-1), but not HSV-2, binds human galectin-3.
12 tor, as well as profibrotic proteins such as galectin-3.
13 ors become upregulated, including the lectin galectin-3.
14 thelial cell surfaces treated with exogenous galectin-3.
15 in fibrotic areas contained large amounts of galectin-3.
16 NKp30 blocking Ab and an inhibitory ligand, galectin-3.
17 luble form of ST2 (33 [24.6-48.1] ng/mL) and galectin 3 (17.8 [14.1-22.8] ng/mL) were higher, and for
23 nal analyses, circulating baseline levels of galectin-3, a protein involved in myocardial fibrosis an
24 the staphylococcal protease SspB inactivates galectin-3, abrogating its stimulation of oxygen radical
25 ted with rapid decline in eGFR (per 1-SD log-galectin-3; adjusted odds ratio [OR], 1.49; 95% confiden
26 te the biological counterreceptor MUC16 from galectin-3 affinity columns, suggesting that association
31 lso observed colocalization between YopD and Galectin-3, an indicator of endosomal membrane damage.
32 onic anhydrase-12, and NC markers brachyury, galectin-3 and CD24 in cells of the NP irrespective of a
35 in promoting MUC16's binding affinity toward galectin-3 and in causing retention of the lectin on the
40 us approximately 10S particle that contained galectin-3 and U1 snRNP and this particle was sufficient
42 (the human adhesion/growth-regulatory lectin galectin-3) and its consequences in structural terms wer
43 5 (growth differentiation factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before
45 brogated by bacterium-derived proteolysis of galectin-3, and SspB was identified as the major proteas
47 nti-fibronectin antibody and beta-lactose, a galectin-3 antagonist, significantly blocked DC exosome-
49 egative form of galectin-3, Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated
51 C50 values for known carbohydrate ligands of galectin-3 are in good agreement with the Kd values repo
52 omatography based on their binding or not to galectin-3, are targeted to kinetically different endocy
58 disruption and pharmacological inhibition of galectin-3 attenuates cardiac fibrosis, LV dysfunction,
59 rn blot, an intact ( approximately 28.0 kDa) galectin-3 band was identified in tear samples from heal
62 In murine mammary epithelial cancer cells, galectin-3 binding to beta1,6-acetylglucosaminyltransfer
67 roteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein) improved risk prediction and
72 chomonas CPI-GC that had reduced affinity to galectin-3 but maintained affinity to galectin-1 suppres
73 endocytic pathways in HFL-1 cells expressing galectin-3 but not in SKBR3 cells lacking galectin-3; th
74 uctures; the MDA-MB-231 cells had no surface galectin-3 but used surface galectin-1 for interaction w
76 with the Kd values reported and measured for galectin-3 by isothermal titration calorimetry (ITC).
78 suggest that once extracellularly released, galectin-3 can act as a damage-associated molecular patt
79 d phase separation, and we demonstrated that galectin-3 can also undergo liquid-liquid phase separati
83 ectin-3 levels over time, from a low to high galectin-3 category, were associated with significantly
84 activating polypeptide II, ectodysplasin A2, Galectin-3, chemokine (C-X-C motif) ligand 2, Nidogen1,
94 nt interactions of transmembrane mucins with galectin-3 contribute to maintenance of the epithelial b
97 istration of a neutralizing antibody against galectin-3 decreases the expression of IL-1beta, IL-6, T
98 anti-inflammatory properties by assembling a galectin-3-Dectin-1-FcgammaRIIB receptor complex that ac
105 cretion systems into PV membranes stimulates Galectin-3-dependent recruitment of antimicrobial GBPs t
108 tic liver injury, we generated dnTGF-betaRII/galectin-3(-/-) (dn/Gal3(-/-)) mice, which showed impair
114 tion of galectin-3 protein in tears, but not galectin-3 expression in conjunctival epithelium, was si
115 ied in human infectious disease, we examined galectin-3 expression in mycobacterial infection by stud
116 studies concerning clinical implications of galectin-3 expression in patients with acute myeloid leu
118 use model of transverse aortic constriction, galectin-3 expression was markedly up-regulated in the p
119 leomorphism, fibrous septation and increased galectin-3 expression, consistent with atypical parathyr
126 ing were used to investigate the function of galectin-3 (Gal-3) during the process of leukocyte recru
129 Mammalian beta-galactoside-binding protein Galectin-3 (Gal-3) modulates the host innate and adaptiv
132 nflammation markers soluble (s)CD163, sCD14, galectin-3 (Gal-3), and Gal-3 binding protein (Gal-3BP)
133 n (beta-lactose, a dominant-negative form of galectin-3, Gal-3C, and anti-galectin-3 antibody M3/38)
134 hree different endocytic ligands-folic acid, galectin-3 (Gal3) and the Shiga toxin B-subunit (STxB).
139 ng protein (gal3bp) and its receptor/ligand, galectin-3 (gal3), are secreted proteins that initiate s
142 show that a beta-galactoside-binding lectin [galectin-3 (gal3)] that recognizes the Thomsen-Friedenre
143 tandem repeats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA pr
144 bitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrot
145 33 ng/mL soluble form of ST2 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those a
153 ect activation of integrin with Mn2+ induces galectin-3, ILK, and Src-dependent RhoA activation and c
155 ain of L. major, LV39, was infected, lack of galectin-3 impaired neutrophil recruitment in the footpa
157 We investigated the potential function of galectin-3 in cell-mediated immunity using peripheral bl
160 e show a large increase in the expression of galectin-3 in microglia and also an increase in the rele
161 In this study, we investigated the role of galectin-3 in neutrophil migration and the biological si
165 esis, cultured fibroblasts were treated with galectin-3 in the absence or presence of galectin-3 inhi
166 and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after h
167 mes detected the presence of fibronectin and galectin-3 in those derived from DCs, whereas T-cell exo
168 the expression of LGALS3, the gene encoding galectin-3, in the bone marrow (BM) mononuclear cells fr
171 ates but not in Staphylococcus saprophyticus Galectin-3-induced activation of the neutrophil NADPH ox
172 of CD146 expression completely abolished the galectin-3-induced secretion of IL-6 and G-CSF cytokines
173 on endothelial cell surfaces responsible for galectin-3-induced secretion of metastasis-promoting cyt
175 sing cell-based assays, indirectly linked to galectin-3 inhibition, showed no inhibition of galectin-
177 r to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that block
179 ollagen binding sites, such as revacept, and galectin-3 inhibitors in the prevention of colon cancer
181 ur results indicate that release of cellular galectin-3 into tears is associated with epithelial dysf
189 bers present in synovial fluid, we find that galectin-3 is a specific, high-affinity binding partner
192 how expression of the inflammatory modulator galectin-3 is controlled, opening up avenues for potenti
194 enabling multivalency for various functions, galectin-3 is monomeric, and its functional multivalency
195 to initiate neutrophil migration even though galectin-3 is not a chemoattractant for neutrophils.
196 ts potential role as a prognostic biomarker, galectin-3 is not a critical modulator of cardiac fibros
197 The beta-galactoside-binding animal lectin galectin-3 is predominantly expressed by activated macro
205 7 days of pressure overload, whereas female galectin-3 knockouts had delayed dilation after 28 days
206 e decompensated HF, repeated measurements of galectin-3 level provided important and significant prog
208 mortality compared with stable or decreasing galectin-3 levels (hazard ratio in CORONA, 1.60; 95% con
213 t cardiomyocyte- but not macrophage-specific galectin-3 localization was associated with adverse remo
215 ar surface, the carbohydrate-binding protein galectin-3 maintains barrier function by cross-linking t
216 2 (an interleukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III
218 suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other p
221 hat CD146/MCAM interactions with circulating galectin-3 may have an important influence on cancer pro
222 t clinical outcome in patients with AML, and galectin-3 may serve as a potential therapeutic target i
225 acterial load or lesion size was detected in galectin-3(-/-) mice, which overall showed smaller lesio
226 tumorgenicity 2, highly sensitive troponin, galectin-3, midregional proadrenomedullin, cystatin-C, i
228 anti-galectin-3 immunoprecipitation of free galectin-3 molecules not in a complex with U1 snRNP (fra
229 as biotinylated asialofetuin (biotin-ASF), a galectin-3 nanomolar binding partner, was bound to strep
230 initial parasite burden remained similar in galectin-3 null mice as compared with wild-type mice.
231 inding ligand and strongly co-localized with galectin-3 on endothelial cell surfaces treated with exo
234 alysis for candidate protein markers such as galectin-3, or analysis of differential microRNA express
235 th inhibitors of scavenger receptor class B, galectin-3, or blocking antibodies against CD36, suggest
237 by baseline level of soluble form of ST2 and galectin 3; patients with values less than the observed
241 y correlates with GFR in humans, but whether galectin-3 predicts incident kidney disease is unknown.
242 ds its cognate elements (CACCC boxes) in the galectin-3 promoter and represses its activation in cell
245 quantitative Western blot, using recombinant galectin-3 protein to generate a calibration curve.
246 epithelial dysfunction in dry eye, and that galectin-3 proteolytic cleavage may contribute to impair
247 that association of transmembrane mucins to galectin-3 provides protection against viral infection.
254 ats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1
255 e B activity, with subsequent impact on C4S, galectin-3, Sp1, and Wnt9A and can exert significant eff
257 ive hazard of adverse event than those whose galectin-3 stayed within +/-15% of the baseline value, i
258 In vitro, cytokine stimulation suppressed galectin-3 synthesis by macrophages and cardiac fibrobla
261 ersican promoter activity increased, and the galectin-3 that co-immunoprecipitated with C4S declined.
262 ng galectin-3 but not in SKBR3 cells lacking galectin-3; the SKBR3 cells, however, can acquire the ab
265 , these results indicate that HSV-1 exploits galectin-3 to enhance virus attachment to host cells and
266 er regulating this recycling, the binding of galectin-3 to particular glycoforms of transferrin.
267 rects cytosolic carbohydrate-binding protein Galectin-3 to PVs and that the delivery of GBP1 and GBP2
270 w document that this interaction between the galectin-3-U1 snRNP particle and the pre-mRNA results in
271 depleted extract can be reconstituted by the galectin-3-U1 snRNP particle, isolated by immunoprecipit
273 ve lepromatous form of leprosy; in contrast, galectin-3 was almost undetectable in self-limited tuber
288 ng affinities to peanut agglutinin and human galectin-3 were measured by isothermal titration calorim
289 rms a lattice with the N-glycan of TRPV5 via galectin-3, which impairs TRPV5 endocytosis and increase
291 We have shown previously that circulating galectin-3, which is increased up to 30-fold in cancer p
292 We demonstrate that melanocytes express galectin-3, which is predominantly localized to the cell
293 The method employs a (89)Zr-labeled mAb to galectin-3, which shows high specificity and binding aff
294 erived from IGHV4-34 using PCNSL, recognized galectin-3, which was upregulated on microglia/macrophag
296 sion models to evaluate associations between galectin-3 with incident renal outcomes at examination 8
297 ic peptides, adrenomedullin, endothelin, and galectin-3 with new-onset HF was stronger in the high-ri
298 These data demonstrate an association of galectin-3 with unfavorable host response in leprosy and
299 is partly attributable to the interaction of galectin-3 with unknown receptor(s) on vascular endothel
300 iguingly, YopK limited the colocalization of Galectin-3 with YopD, suggesting that YopK limits the in
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。